TCRT Alaunos Therapeutics Inc

Price (delayed)

$0.651

Market cap

$10.42M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.86

Enterprise value

$6.28M

Ziopharm Oncology is an immuno-oncology company focused on developing end-to-endcost-effective solutions using its non-viralSleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 ...

Highlights
Alaunos Therapeutics's debt has plunged by 100% YoY
The company's quick ratio has surged by 52% YoY and by 8% QoQ
The gross profit has dropped by 100% year-on-year
The revenue has plunged by 100% YoY

Key stats

What are the main financial stats of TCRT
Market
Shares outstanding
16.01M
Market cap
$10.42M
Enterprise value
$6.28M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.18
Price to sales (P/S)
2,084.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,255.83
Earnings
Revenue
$5,000
EBIT
-$25.71M
EBITDA
-$23.91M
Free cash flow
-$21.31M
Per share
EPS
-$1.86
Free cash flow per share
-$1.33
Book value per share
$0.3
Revenue per share
$0
TBVPS
$0.38
Balance sheet
Total assets
$6.04M
Total liabilities
$1.24M
Debt
$0
Equity
$4.8M
Working capital
$4.8M
Liquidity
Debt to equity
0
Current ratio
4.87
Quick ratio
3.34
Net debt/EBITDA
0.17
Margins
EBITDA margin
-478,240%
Gross margin
100%
Net margin
-535,480%
Operating margin
-526,760%
Efficiency
Return on assets
-173.7%
Return on equity
-229.6%
Return on invested capital
-934%
Return on capital employed
-535.9%
Return on sales
-514,120%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TCRT stock price

How has the Alaunos Therapeutics stock price performed over time
Intraday
0.15%
1 week
1.72%
1 month
-31.47%
1 year
38.51%
YTD
820.79%
QTD
-7%

Financial performance

How have Alaunos Therapeutics's revenue and profit performed over time
Revenue
$5,000
Gross profit
$5,000
Operating income
-$26.34M
Net income
-$26.77M
Gross margin
100%
Net margin
-535,480%
The gross profit has dropped by 100% year-on-year
The revenue has plunged by 100% YoY
TCRT's net income is up by 30% year-on-year and by 24% since the previous quarter
The company's operating income rose by 26% YoY and by 23% QoQ

Growth

What is Alaunos Therapeutics's growth rate over time

Valuation

What is Alaunos Therapeutics stock price valuation
P/E
N/A
P/B
2.18
P/S
2,084.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,255.83
Alaunos Therapeutics's EPS has increased by 30% YoY and by 15% from the previous quarter
TCRT's equity has shrunk by 84% YoY and by 24% QoQ
The price to book (P/B) is 59% lower than the 5-year quarterly average of 5.3 and 48% lower than the last 4 quarters average of 4.2
The revenue has plunged by 100% YoY
The price to sales (P/S) is 27% lower than the last 4 quarters average of 2834.6

Efficiency

How efficient is Alaunos Therapeutics business performance
The company's return on assets has shrunk by 191% YoY and by 29% QoQ
The ROIC has shrunk by 155% YoY and by 27% QoQ
The return on equity has dropped by 112% year-on-year and by 17% since the previous quarter
Alaunos Therapeutics's ROS has increased by 23% from the previous quarter

Dividends

What is TCRT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TCRT.

Financial health

How did Alaunos Therapeutics financials performed over time
Alaunos Therapeutics's current ratio has soared by 117% YoY and by 15% from the previous quarter
The total liabilities has plunged by 94% YoY and by 37% from the previous quarter
Alaunos Therapeutics's debt is 100% less than its equity
Alaunos Therapeutics's debt has plunged by 100% YoY
The debt to equity has dropped by 100% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.